Scientists Question the Reality of Blue Zones After Landmark Genetic Study

In 2022, French geneticist Jean-François Deleuze launched the AGENOMICS study, a groundbreaking research project designed to uncover genetic patterns among 1,200 French centenarians—individuals who had lived beyond 100 years. His goal was to compare these genetic profiles with those of centenarians from one of the world’s most famous “blue zones.”

But as the study progressed, Deleuze’s initial optimism began to wane. The early results raised unexpected questions about the validity of blue zones—regions like Okinawa, Japan, and Sardinia, Italy, long celebrated for their unusually high concentrations of centenarians.

Blue zones have been widely cited in longevity research, popular media, and even public health campaigns. These areas are often held up as proof that specific lifestyle, diet, and environmental factors can significantly extend human lifespan. However, Deleuze’s findings suggest that the genetic evidence supporting these claims may not be as robust as previously believed.

What are blue zones?

Blue zones are geographic regions identified by researchers as having an unusually high number of people who live to 100 years or older. The concept was popularized by journalist Dan Buettner, who, in collaboration with National Geographic, identified five such zones:

• Okinawa, Japan – Known for its low-calorie diet and strong social networks.
• Sardinia, Italy – Particularly the province of Nuoro, where men often live exceptionally long lives.
• Nicoya Peninsula, Costa Rica – Characterized by a diet rich in beans, corn, and squash.
• Ikaria, Greece – An island where traditional Mediterranean diets and active lifestyles are common.
• Loma Linda, California, USA – Home to a community of Seventh-day Adventists with a focus on plant-based diets and regular exercise.

The blue zones hypothesis suggests that these regions share common lifestyle factors—such as plant-based diets, strong social ties, and regular physical activity—that contribute to longevity. However, Deleuze’s study challenges this narrative by questioning whether genetics play a more significant role than previously acknowledged.

Challenges to the blue zones theory

Deleuze’s research, which is still ongoing, has already begun to cast doubt on the genetic uniqueness of blue zone populations. Early data indicates that the genetic patterns observed among French centenarians do not significantly differ from those in blue zones. This raises critical questions:

• Are blue zones truly exceptional, or are they simply regions where longevity is more visible due to better record-keeping?
• Do lifestyle factors alone account for the high number of centenarians, or is genetics a more dominant factor?
• Could the blue zones phenomenon be overstated due to selection bias in how these regions were identified?

“The idea that blue zones are genetic hotspots for longevity is not holding up under scrutiny,” Deleuze stated in an interview. “We’re seeing that genetics may play a role, but it’s not the defining factor we once thought.”

Implications for longevity research

The findings from the AGENOMICS study could have far-reaching implications for how scientists and policymakers approach longevity research. If blue zones are not as genetically unique as believed, it may shift the focus toward other factors—such as healthcare access, socioeconomic conditions, or even luck—that contribute to long life.

For example, regions with better healthcare infrastructure might naturally have more centenarians, not because of a unique genetic advantage, but because people live longer due to improved medical care. Similarly, areas with strong social support systems may foster environments where people are more likely to reach advanced ages.

What’s next for blue zones research?

Deleuze and his team plan to continue analyzing the genetic data from the AGENOMICS study, with results expected in late 2024. In the meantime, the study has sparked a broader debate within the scientific community about the validity of blue zones as models for longevity.

Some researchers argue that blue zones should still be studied, but with a more critical lens. Others believe the concept has been overhyped and that resources would be better spent exploring other avenues of longevity research.

“Blue zones have been a useful narrative for promoting healthy lifestyles, but we can’t let that narrative overshadow the complexity of human longevity,” said Dr. Aubrey de Grey, a prominent longevity researcher. “Genetics, environment, and sheer chance all play a role, and we need to acknowledge that.”